Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Scottish Enterprise. (12/10/19). "Press Release: Current Health Closes £9 Million Series A Funding Round".

Organisations Organisation Scottish Enterprise
  Group Scotland (govt)
  Organisation 2 Current Health Ltd.
Products Product digital health
  Product 2 venture capital
Index term Index term Current Health–SEVERAL: investment, 201912 financing round Series A £9m led by MMC Ventures + incl Legal & General + Par Equity + SIB
Persons Person McCann, Christopher (Current Health 201912 CEO + Co-Founder)
  Person 2 Macfarlane, Bruce (MMC Ventures 201912 Managing Partner)
     


Current Health, which offers the leading FDA-cleared, artificial intelligence (AI)-powered patient management platform, today announced it has closed a £9 million series A funding round led by MMC Ventures.

Legal & General, the FTSE 100 life insurer and asset manager, is Current Health’s first corporate investor and the largest investor in the round as it continues to invest in the future infrastructure of health and care globally. The capital will be used to scale Current Health’s platform, with the goal of preventing illness for one million patients around the world by 2021.

Par Equity and the Scottish Investment Bank, the investment arm of Scottish Enterprise, also participated in this round.

Edinburgh-based Current Health, which was founded in 2015 by CEO Christopher McCann and CTO Stewart Whiting, uses wearable and wireless vital signs monitoring, clinical indicators from an ecosystem of more than 50 integrations and symptoms collected via its patient engagement tools, to continuously track patient health trends. Leveraging proprietary machine learning algorithms, the company’s end-to-end platform analyzes this data to proactively detect illness and alert providers to high-risk patients so they can deliver healthcare earlier.

Today, 13 of the largest healthcare systems in the United States and United Kingdom – including Mount Sinai and Dartford & Gravesham NHS Trust – use Current Health to manage patient care. With the Current Health platform, customers have been able to shorten hospital stays, reduce hospital readmission rates, improve patient satisfaction and deliver better patient outcomes.

"Healthcare is undergoing a paradigm shift from reactive, in-hospital treatment, to proactive, community-based care,” said Bruce Macfarlane, Managing Partner at MMC Ventures. “Today’s healthcare systems must deliver improved patient outcomes while reducing costs. Current Health’s revolutionary solution offers unprecedented insight into patients’ health. Reliable, continuous patient monitoring enables earlier intervention in the event of patient deterioration, better patient experiences and fewer unnecessary hospital readmissions. With its world-class team and platform, Current Health has the right fundamentals to execute on a vast opportunity and become a global category leader in this important market.”

Current Health has secured three FDA 501(k) clearances for its platform and proven the value of its solution in some of the most demanding and respected healthcare systems in the world. In the past 12 months, it has also:

- Grown revenue by more than 300%

- Partnered with two of the world’s largest pharmaceutical companies to extend the power of the Current Health platform to thousands of patients

- More than doubled its employee count

- Added key members to its executive team – including COO Richard Lennox and VP of Sales Sean Ginney – to steer the company’s growth

“We’ve spent the last three years quietly and carefully building and testing our platform directly with healthcare providers,” said McCann. “Now, with our platform FDA-cleared and through partnerships with some of the biggest healthcare providers and pharmaceutical companies in the world, we plan to scale our solution to better treat millions of lives over the next five years. By helping healthcare providers treat patients preventively and at the earliest point, we can play a key role in enabling sustainable, high-quality and universal healthcare delivery.”

As Current Health embarks on the next stage of its growth, it will open a U.S. headquarters in New York City. The company will continue to expand its team, particularly in the sales, clinical operations and marketing functions.

Chris Knight, CEO, Legal & General Retail Retirement, said: “Current Health is helping change the fundamentals of healthcare by expanding the accessibility and affordability of care through its patient management platform. We strongly believe in its mission and approach and are excited to partner with the company as it continues to scale its solution globally. Our investment in Current Health reinforces our commitment to provide innovative solutions to help improve personal well-being. It demonstrates our commitment to help people live longer, healthier, happier lives.”

Robert Higginson, Partner, Par Equity: “Par Equity was the first investor into Current Health in 2016 and we are delighted to continue our hands-on support of the business. Having helped the company establish itself in the early years and provide support in the U.S., it’s particularly pleasing to see Current Health developing into a global HealthTech business, improving quality of care for patients.”

Kerry Sharp, Director, Scottish Investment Bank, added: “Current Health was established to help healthcare professionals keep people healthy and alive. In a very short period of time, the company has taken its idea of proactive healthcare and developed scalable platform technology capable of achieving that aim. We are genuinely excited to continue our support for Current Health’s domestic and international growth.”


Contact Information
Ross Nisbet

ross.nisbet@scotent.co.uk

   
Record changed: 2020-05-16

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for Scotland (govt)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top